Thymalin vs Cardiogen: which one actually has evidence behind it

Search "thymalin vs cardiogen" and you'll mostly find the same peptide directory copy pasted across a dozen vendor sites, none of it distinguishing between a compound with real decades-old cohort data and one with almost nothing behind it. Short answer: run Thymalin if you want a Khavinson-family bioregulator with an actual human evidence trail, and treat Cardiogen as speculative until something better than animal-family theory shows up, because that is the current state of the literature.

I get asked about these two together a lot, usually from people who found both on the same supplier's Khavinson-family page and assumed they were interchangeable options for the same goal. They are not. Thymalin targets the thymus and immune aging. Cardiogen targets cardiomyocytes and cardiac tissue maintenance. Different organ, different theoretical mechanism, and wildly different amounts of evidence sitting behind each one.

The evidence gap is not close

Thymalin is the founding member of the Khavinson short-peptide bioregulator family, going back to 1970s Soviet military medicine research on tissue-specific extracts. It carries the deepest human record in that entire 13-member family. A 266-patient elderly cohort followed for six to eight years reported a two to four-fold reduction in mortality when Thymalin was paired with a related peptide called Epithalamin (Khavinson & Morozov 2003), with a companion paper from the same research group covering the geroprotective angle on that cohort (Khavinson & Morozov 2002). A 156-patient study on ischemic heart disease reported normalized lipid metabolism and improved cardiac function (Shustval' 1992). More recently, Thymalin added to standard COVID-19 therapy was reported to speed the decline of inflammatory markers like IL-6 and D-dimer and reduce thrombosis risk (Khavinson, Kuznik et al. 2021).

None of that is a randomized controlled trial. It's all single-research-group Russian cohort work, and Western reviewers are right to discount it on methodology grounds. But it is a real, decades-deep dataset, and that puts it in a different category than most of its family siblings.

Cardiogen does not have that. The peptide directory most vendors pull their numbers from lists Cardiogen at "Moderate, 9 human studies," which sounds reassuring until you actually pull the papers. What you find is a citation mismatch: those studies are about "CardioGen-82," a rubidium-82 PET imaging generator used in cardiac scans, plus an unrelated Hungarian cardiomyopathy registry (the imaging-generator paper is here). None of it is about the Khavinson peptide at all. Strip that mismatch out and Cardiogen sits at the same level as thymus-derived nuclear-penetration work done in vitro on the broader family, which shows short Khavinson peptides can enter cell nuclei and interact with DNA promoter regions. That's a plausible mechanism story, not evidence that the cardiac-specific compound does anything in a living person.

Cost and side-effect load

Cost tends to track evidence depth in this family too. Thymalin, because it has an actual clinical-use approval in Russia and enough demand history to have a real manufacturing footprint, is generally easier to source consistently and from more suppliers. Cardiogen is a thin-demand, provisional-tier product, and thinner demand usually means fewer vendors bothering to keep consistent stock, which in this specific family matters more than usual: Khavinson-family peptides are the most heavily counterfeited category in the whole peptide space, and a compound nobody has published on is an easy one to mislabel since there's no independent literature to check a seller's claims against.

Side effects for both are drawn from the same family-wide profile: occasional injection-site reactions and transient mild headache early in a cycle, nothing more serious documented in the Russian literature. Neither peptide has a distinct safety signal that separates it from the other. The difference is entirely on the evidence and sourcing side, not the risk side.

Before you write any of this down, the obligatory: The doses and schedules here are for educational and informational purposes only. These peptides are sold for research use only and are not FDA-approved drugs. This is not medical advice. Consult a qualified physician before beginning any protocol.

Dosing, and who each one actually suits

The studies behind Thymalin used small intramuscular doses in short in-clinic courses, since it's a tissue extract rather than a single synthesized sequence and its dosing convention differs from the family's synthetic members. The real-world protocol people run, extrapolated from that and from the broader Khavinson cycle pattern, is a 10 to 20 day course repeated two to three times a year, with the claimed benefit persisting a couple of months past the end of the cycle. Cardiogen has no dose-finding data specific to it at all, so anyone running it is borrowing the generic family convention of roughly 100 to 200 mcg per day over a similar 10 to 20 day cycle, which is a much bigger extrapolation than the one behind Thymalin's numbers.

I try to stay evidence-based with peptides, and that shapes who I think each of these fits. Thymalin suits someone specifically interested in the Khavinson-family longevity and immune-support thesis who is comfortable weighing decades of non-randomized cohort data against the lack of a Western trial. Cardiogen suits almost nobody yet except someone deliberately experimenting at the frontier of this family and accepting that they are running on theoretical mechanism alone. If cardiac support is the actual goal, I would rather see someone spend that budget on lifestyle levers with real data behind them, or talk to their doctor about what's actually driving the concern, before reaching for a peptide with essentially no peptide-specific human evidence.

If you're weighing this alongside other Khavinson-family choices, the Thymalin encyclopedia entry and the Cardiogen entry both go deeper on mechanism and sourcing, and the piece on reading a peptide certificate of analysis is worth reading before you buy either one, since verification matters more here than almost anywhere else in the catalog.

Heads up: OHM has an affiliate relationship with the vendors linked here, so we earn a commission if you buy through one of these links. It costs you nothing extra and it does not change which peptide the evidence supports. I'd rather point you at the one with a real track record and still make the commission than push the one with nothing behind it.

Where Cardiogen goes from here depends entirely on whether anyone runs an actual peptide-specific trial. Until then, one of these two compounds has decades of flawed but real cohort data behind it, and the other has a citation-matching error that got mistaken for evidence.